Roundview Capital LLC Purchases 3,021 Shares of West Pharmaceutical Services, Inc. $WST

Roundview Capital LLC grew its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 385.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,804 shares of the medical instruments supplier’s stock after purchasing an additional 3,021 shares during the quarter. Roundview Capital LLC’s holdings in West Pharmaceutical Services were worth $1,047,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of WST. Elyxium Wealth LLC bought a new position in shares of West Pharmaceutical Services during the 4th quarter valued at about $25,000. CYBER HORNET ETFs LLC bought a new position in shares of West Pharmaceutical Services during the 2nd quarter valued at about $25,000. Private Trust Co. NA increased its position in shares of West Pharmaceutical Services by 156.4% during the 4th quarter. Private Trust Co. NA now owns 100 shares of the medical instruments supplier’s stock valued at $28,000 after purchasing an additional 61 shares during the last quarter. International Assets Investment Management LLC bought a new position in shares of West Pharmaceutical Services during the 4th quarter valued at about $31,000. Finally, Torren Management LLC bought a new position in shares of West Pharmaceutical Services during the 4th quarter valued at about $34,000. 93.90% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have recently commented on WST. Evercore reiterated an “outperform” rating on shares of West Pharmaceutical Services in a research report on Friday, April 24th. Barclays lifted their target price on shares of West Pharmaceutical Services from $275.00 to $310.00 and gave the stock an “equal weight” rating in a research report on Monday, April 27th. UBS Group reiterated a “buy” rating and issued a $340.00 target price on shares of West Pharmaceutical Services in a research report on Friday, February 13th. Zacks Research upgraded shares of West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, May 13th. Finally, Citigroup reiterated a “buy” rating on shares of West Pharmaceutical Services in a research report on Friday, April 24th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $322.89.

Insider Transactions at West Pharmaceutical Services

In other news, VP Annette F. Favorite sold 2,817 shares of the stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $305.20, for a total transaction of $859,748.40. Following the completion of the sale, the vice president directly owned 16,828 shares in the company, valued at approximately $5,135,905.60. This represents a 14.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Chad Winters sold 896 shares of the stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $300.67, for a total transaction of $269,400.32. Following the sale, the chief accounting officer owned 1,523 shares of the company’s stock, valued at approximately $457,920.41. This represents a 37.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.60% of the company’s stock.

West Pharmaceutical Services Stock Performance

Shares of WST stock opened at $312.22 on Thursday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.04 and a current ratio of 2.71. West Pharmaceutical Services, Inc. has a fifty-two week low of $206.10 and a fifty-two week high of $330.88. The stock has a 50 day moving average price of $280.24 and a two-hundred day moving average price of $266.97. The company has a market capitalization of $22.06 billion, a P/E ratio of 41.74, a PEG ratio of 2.65 and a beta of 1.17.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share for the quarter, beating the consensus estimate of $1.68 by $0.45. West Pharmaceutical Services had a return on equity of 19.03% and a net margin of 16.85%.The firm had revenue of $844.90 million during the quarter, compared to the consensus estimate of $779.68 million. During the same quarter in the previous year, the company posted $1.45 earnings per share. The business’s revenue was up 21.0% on a year-over-year basis. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. Analysts expect that West Pharmaceutical Services, Inc. will post 8.6 earnings per share for the current year.

West Pharmaceutical Services announced that its board has authorized a stock repurchase plan on Tuesday, February 17th that authorizes the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization authorizes the medical instruments supplier to buy up to 5.6% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s leadership believes its stock is undervalued.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.